Starling Oncology (STLNW) Amortization of Deferred Charges (2021 - 2026)

Starling Oncology (STLNW) has reported Amortization of Deferred Charges for 6 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Amortization of Deferred Charges rose 11.25% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.8 million (down 47.26% YoY), and the FY2025 full-year result was $8.4 million, up 32.91% from the prior year.
• Amortization of Deferred Charges grew to $1.3 million in Q2 2026 per STLNW's latest filing, from $1.2 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $4.9 million in Q1 2025 and bottomed at $892000.0 in Q3 2022.
• Historically, Amortization of Deferred Charges has averaged $1.6 million across 5 years, with a median of $1.5 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Amortization of Deferred Charges surged 4855.56% in 2022, then plunged 75.15% in 2026.
• Over 5 years, Amortization of Deferred Charges stood at $1.6 million in 2022, then climbed by 1.29% to $1.6 million in 2023, then advanced by 1.4% to $1.6 million in 2024, then decreased by 24.4% to $1.2 million in 2025, then grew by 4.23% to $1.3 million in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $1.3 million, $1.2 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.